ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 150

PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice

Maida Wong1 and Bevra H Hahn2, 1Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA, 2Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: PD-1, T-Regulatory Cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD-1), a negative regulator in T cells, limits certain T cell-mediated immune responses. Increased PD-1 expression on T cells inhibits cell activation and proliferation and its blockade reinstates immune cell function. Our laboratory has shown that attenuated, but not absent, PD-1 signaling enables CD4+ regulatory T cells (Treg) to survive and suppress helper T cells Th and B cells. Gene array data have shown that attenuated PD-1 expression in Treg down-regulates several members of the TNF receptor family, including OX40L. It has been reported that OX40L is up-regulated in immune cells from patients with autoimmune disease by promoting follicular helper and effector memory T cells, and suppressing Treg proliferation. We hypothesize that one mechanism by which PD-1 sustains Treg proliferation and suppressive function is by reducing OX40L expression on Treg.

Methods:

We treated lupus-prone BWF1 mice with a neutralizing Ab against PD-1 or control isotype-matched IgG intraperitoneally. OX40L, Foxp3 and PD-1 expression on Treg from the spleens was measured by flow cytometry. Treg were cocultured with unmanipulated CD4+CD25– Th and B cells, and cell proliferation/apoptosis of Treg, Th and B cells was measured with CFSE/Annexin V by flow cytometry. Cytokine production namely IFNγ (Th1), IL-4 (Th2), IL-17a (Th17) and TGF-β (Treg), and anti-dsDNA (B cells) in the culture media were measured by ELISA. To test the plasticity of these Treg, we treated Treg with agonistic vs antagonistic OX40L Ab in vitro, and set up the coculture experiments and determined cell proliferation and cytokine production as described above.

Results:

OX40L expression was lower in PD1loTreg from anti-PD1-treated mice when compared to PD1hiTreg from controls. OX40LhiTreg, irrespective to its Foxp3 expression, lost its ability to suppress Th and B proliferation. PD1loTreg treated with agonistic OX40L had attenuated suppressive function: there was decreased production of TGF-β, increased proliferation of Th (Th1 predominant) and increased anti-DNA production. These Treg also had increased apoptosis. Treating PD1hiTreg with antagonistic OX40L could not restore the suppressivity in Treg.

Conclusion:

Effective induction of Treg is associated with low expression of PD-1, which permits cells to survive and perform cell suppressive function. Attenuated PD-1 expression in Treg reduces OX40L expression on Treg, which helps restore the suppressive capacity and proliferation of Treg. Increased OX40L expression overrides PD-1 signaling to deactivate and induce apoptosis in Foxp3+Treg, but reduced OX40L expression cannot recover Treg suppressivity when PD-1 signal is high. The suppressive function induced by low PD-1 expression is influenced by the intensity of OX40L expression. PD-1 and OX40L signaling most likely crosstalk to regulate the suppressive capacity and survival of Treg to achieve peripheral tolerance in SLE.


Disclosure: M. Wong, None; B. H. Hahn, Janssen Research & Development, LLC, 2.

To cite this abstract in AMA style:

Wong M, Hahn BH. PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/pd-1-signaling-interferes-with-ox40l-to-alter-the-suppressive-function-and-proliferation-of-cd4-regulatory-t-cells-in-lupus-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pd-1-signaling-interferes-with-ox40l-to-alter-the-suppressive-function-and-proliferation-of-cd4-regulatory-t-cells-in-lupus-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology